Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase NA 3Phase 3 2Phase 2/3 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Unknown 25Recruiting 5Not yet recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × camrelizumab × Clear all
NCT06124001 2023-11-15

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

CNBG-Virogin Biotech (Shanghai) Ltd.

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06010212 2023-08-24

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡